48 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26314922	2	Imidazopyridines as a source of biological activity and their pharmacological potentials-Infrared and Raman spectroscopic evidence of their content in pharmaceuticals and plant materials.	Wroclaw University of Economics
20493713	30	Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.	Uppsala University
10821712	18	Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity.	Neogenesis
8576904	78	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.	Dupont Pharmaceuticals
	32	L-161,638: A potent AT2selective quinazolinone angiotensin II binding inhibitor	TBA
	17	1,4-substituted indoles: a potent and selective class of angiostensin II receptor antagonists	TBA
	24	The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists	TBA
	10	L-162,389: a potent orally active angiotensin II receptor antagonist with balanced affinity to both AT1 and AT2 receptor subtypes	TBA
	54	4,5-Dihydro-4-oxo-3H-imidazo[4,5-c]pyridines: potent arylacetic acid-derived AT1 antagonists with improved affinity for the AT2 receptor	TBA
	54	α-Phenoxyphenylacetic acid derived angiotensin II antagonists with low nanomolar AT1/AT2 receptor subtype affinity (Part II)	TBA
	8	Substituted 1,3-benzodioxole & 1,3-benzodithiole -2- carboxylates and their tetrazole analogs with potent binding affinity to the angiotensin II AT1 receptor	TBA
	56	Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the AT1 and AT2 subtypes	TBA
	134	Development of angiotensin II antagonists with equipotent affinity for human AT1 and AT2 receptor subtypes.	TBA
	46	Balanced angiotensin II receptor antagonists. I. The effects of biphenyl “ortho”-substitution on AT1/AT2 affinities	TBA
	54	A new class of balanced AT1/AT2 angiotensin II antagonists: quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalities	TBA
	36	Quinazolinone Biphenyl Acylsulfonamides: A potent new class of angiotensin-II receptor antagonists	TBA
	50	Potent imidazole angiotensinII antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacements	TBA
	8	Synthesis of new imidazo[1,2-b]pyridazine isosteres of potent imidazo[4,5-b]pyridine angiotensin II antagonists	TBA
	24	Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors	TBA
	42	Imidazo[4,5-b]pyridine-based AT1 / AT2 angiotensin II receptor antagonists	TBA
	19	Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamide	TBA
	10	Angiotensin II receptor antagonists containing a phenylpyridine element.	TBA
	56	Synthesis and structure-activity relationships of a novel series of non-peptide AT2-selective angiotensin II receptor antagonists	TBA
17125268	44	Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships.	Uppsala University
32030982	14	The Other Angiotensin II Receptor: AT	Centre Hospitalier Universitaire Vaudois (Chuv) and University of Lausanne (Unil
8421274	27	Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.	Searle
8277506	58	Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.	Merck Research Laboratories
8277505	58	Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.	Merck Research Laboratories
8258820	47	A novel series of selective, non-peptide inhibitors of angiotensin II binding to the AT2 site.	Dupont Pharmaceuticals
8246245	26	(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.	Merck Research Laboratories
8230109	18	A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor.	Merck Research Laboratories
8201597	10	Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine derivatives.	E. Merck
8064808	202	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.	Merck Research Laboratories
8057285	44	Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.	Carpibem
7990105	16	A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.	Merck Research Laboratories
7799397	86	Triazolinone biphenylsulfonamides as angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes.	Merck Research Laboratories
7636854	22	Balanced AT1/AT2 receptor antagonists. 4. XR510 and related 5-(3-amidopropanoyl)imidazoles possessing equal affinity for the AT1 and AT2 receptors.	Dupont Pharmaceuticals
7562905	258	Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.	Merck Research Laboratories
2016730	14	1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.	Smithkline Beecham Pharmaceuticals
26833890	18	Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease.	Yogi Vemana University
25665518	18	2,3-Dihydroquinazolin-4(1H)-one derivatives as potential non-peptidyl inhibitors of cathepsins B and H.	Kurukshetra University